"Russia Pharmaceuticals & Healthcare Report Q4 2014" Published

From: Fast Market Research, Inc.
Published: Wed Nov 05 2014

Russia's cooling of relations with the West is putting pressure on foreign investment in the country. With the EU and the US applying further sanctions, the business environment in the country is deteriorating . As the government push es through protectionist measures, localisation by drugmakers will continue. However, we maintain that o ver the longer term the country's ageing population and significant disease burden will act to underpin pharmaceutical expenditure growth.

Headline Expenditure Projections

* Pharmaceuticals: RUB786.50bn (USD24.68bn) in 2013 to RUB857.34bn (USD24.36bn) in 2014; +9.0% in local currency terms and -1.3% in US dollar terms.
* Healthcare: RUB4,368bn (USD137.06bn) in 2013 to RUB4,608bn (USD130.91bn) in 2014; 5.5% in local currency terms and -4.5% in US dollar terms.

Risk/Reward Ratings: Russia has an RRR score of 56.7 out of 100, making it the fourth most attractive pharmaceutical market in Central and Eastern Europe. Russia has fallen from its previous position of the third most attractive market due to its worsening business environment and depreciating currency. Although Russia scores the highest in the region for Industry Rewards, its overall score is moderated by its lower Risk score, highlighting the challenging operating environment in the country.

Full Report Details at
- http://www.fastmr.com/prod/888578_russia_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Key Trends And Developments

* Prime Minister Dmitry Medvedev and the Minister for Trade and Economy Sergey Tsib have ruled out an outright ban on imports of innovative medicines in Russia following rhetoric on greater import substitution.
* Abbott Laboratories'purchase of Veropharm has been approved by the Federal Antimonopoly Service (FAS).
* The hospital market for pharmaceuticals will continue to deteriorate as the Ministry of Health continues to reduce overcapacity in the hospital sector.
* The Russian state has delayed the full implementation of GMP rules for local factories to 2015 and 2016 in some cases.
* Currency selloffs across emerging...

The Russia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Russia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Russian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Russia to test other views - a key input for successful budgeting and strategic business planning in the Russian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »